{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:08:26Z","timestamp":1792066106196,"version":"4.4.0"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p>Boers J E, Meeuwissen H &amp; Methorst N\u2028(2011) <jats:italic>Histopathology<\/jats:italic><jats:bold>58<\/jats:bold>, 383\u2013394\u2028<jats:bold>HER2 status in gastro\u2010oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two <jats:italic>in situ<\/jats:italic> hybridization methods (FISH and SISH)<\/jats:bold><\/jats:p><jats:p><jats:bold>Aims:\u2002<\/jats:bold> HER2 gene amplification has been detected in 10\u201320% of gastric adenocarcinomas. In view of the recently demonstrated clinical benefit of the anti\u2010human epidermal growth factor receptor 2 (HER2) drug trastuzumab in the treatment of advanced gastric cancer, reliable HER2 testing is of key importance. The aim of this study was to examine HER2 status in gastro\u2010oesophageal adenocarcinomas comparing SP3 and 4B5 immunohistochemistry (IHC) with dual probe HER2 [fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH) and silver <jats:italic>in situ<\/jats:italic> hybridization (SISH)].<\/jats:p><jats:p><jats:bold>Methods and results:\u2002<\/jats:bold> IHC and SISH were carried out on biopsy specimens of 146 patients with adenocarcinomas of the oesophagus and stomach. All SP3\u2010IHC\u2010positive cases and 91% of 4B5\u2010IHC\u2010positive cases were amplified. Sensitivity of SP3\u2010IHC\u2010positivity and 4B5\u2010IHC\u2010positivity for amplification was 77% and 96%, respectively. Results of FISH performed in 42 cases were identical to SISH. Amplification was heterogeneous in 73% of the adenocarcinomas; 24% of the oesophago\u2010gastric carcinomas and 7% of distal stomach tumours were amplified.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> HER2\u2010positivity is present in a significant proportion of oesophago\u2010gastric adenocarcinomas (24%), but at a lower rate in the distal stomach (7%). Sensitivity for amplification is higher with 4B5 IHC than with SP3. FISH and SISH yield identical results, but assessment is much easier with SISH. Our findings provide important guidance for HER2\u2010testing in gastro\u2010oesophageal adenocarcinomas for patients in whom anti\u2010HER2 treatment is considered.<\/jats:p>","DOI":"10.1111\/j.1365-2559.2011.03760.x","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T18:02:20Z","timestamp":1297879340000},"page":"383-394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["HER2 status in gastro\u2010oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two <i>in situ<\/i> hybridization methods (FISH and SISH)"],"prefix":"10.1111","volume":"58","author":[{"given":"James E.","family":"Boers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri\u00ebtte","family":"Meeuwissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Methorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2008.11.014"},{"key":"e_1_2_8_3_2","first-page":"219s","article-title":"HER2\u2010positivity rates in advanced gastric cancer: results from a large international phase III trial","volume":"26","author":"Bang YJ","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2008.03028.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800712"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-100103852"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800729"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.05.008"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.02.005"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-9057-1"},{"key":"e_1_2_8_11_2","first-page":"4819","article-title":"Gene amplification in esophageal adenocarcinomas and Barrett\u2019s with high\u2010grade dysplasia","volume":"9","author":"Miller CT","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi064"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.1.23"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000227222"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10257"},{"key":"e_1_2_8_16_2","first-page":"349","article-title":"erbB\u20102 expression in well\u2010differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection","volume":"115","author":"Motojima K","year":"1994","journal-title":"Surgery"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(00)80195-1"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01629433"},{"key":"e_1_2_8_19_2","first-page":"1381","article-title":"HER2 testing in gastric cancer: molecular morphology and storage time\u2010related changes in archival samples","volume":"23","author":"Risio M","year":"2003","journal-title":"Int. J. Oncol."},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604885"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-8-590"},{"key":"e_1_2_8_23_2","volume-title":"Pathology and genetics of tumours of the digestive system","author":"Hamilton SR","year":"2000"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035010"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000149300.28588.23"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-18-ASOCCO"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.8.4.417"},{"key":"e_1_2_8_28_2","unstructured":"SheppardB.Results of the College of American Pathologists HER2 proficiency exam. BioPerspectives \u2013 the Ventana Newsletter: Tucson AZ:Ventana Medical Systems Inc. 2007."},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.040287"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-007-0424-5"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.053892"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.054866"},{"key":"e_1_2_8_33_2","unstructured":"Nordiqc.Assessment Run B6 2008. Available at:http:\/\/www.nordiqc.org\/Run\u201024\u2010B6\/Assessment\/assessment\u2010HER\u20102.htmed. Acessed January 15 2009."},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e31802ced25"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1159\/000132567"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/PDM.0b013e318161f993"},{"key":"e_1_2_8_37_2","first-page":"761","article-title":"Amplification of the c\u2010erbB\u20102 (HER\u20102\/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization","volume":"151","author":"Ishikawa T","year":"1997","journal-title":"Am. J. Pathol."},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20001"},{"key":"e_1_2_8_39_2","first-page":"65","article-title":"Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer","volume":"15","author":"Yano T","year":"2006","journal-title":"Oncol. Rep."}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2559.2011.03760.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2559.2011.03760.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:24:47Z","timestamp":1697354687000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2559.2011.03760.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1365-2559.2011.03760.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03760.x","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"2011-02-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}